Adult Brain Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Classification of Adult Brain Tumors
This classification is based on the World Health Organization (WHO) classification of central nervous system (CNS) tumors. The WHO approach incorporates and interrelates morphology, cytogenetics, molecular genetics, and immunologic markers in an attempt to construct a cellular classification that is universally applicable and prognostically valid. Earlier attempts to develop a TNM-based classification were dropped: tumor size (T) is less relevant than tumor histology and location, nodal status (N) does not apply because the brain and spinal cord have no lymphatics, and metastatic spread (M) rarely applies because most patients with CNS neoplasms do not live long enough to develop metastatic disease.The WHO grading of CNS tumors establishes a malignancy scale based on histologic features of the tumor. The histologic
Childhood Ependymoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information
The National Cancer Institute provides the PDQ pediatric cancer treatment information summaries as a public service to increase the availability of evidence-based cancer information to health professionals,patients,and the public. In recent decades,dramatic improvements in survival have been achieved for children and adolescents with cancer. Childhood and adolescent cancer survivors require ...
Adult Brain Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Adult Brain Tumors
An adult brain tumor is a disease in which abnormal cells form in the tissues of the brain. There are many types of brain and spinal cord tumors. The tumors are formed by the abnormal growth of cells and may begin in different parts of the brain or spinal cord. Together,the brain and spinal cord make up the central nervous system (CNS). The tumors may be benign (not cancer) or malignant ...
Childhood Astrocytomas Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information
This PDQ summary contains content that is also included in the PDQ Childhood Cerebellar Astrocytoma,PDQ Childhood Cerebral Astrocytoma,and PDQ Childhood Visual Pathway/ Hypothalamic Glioma summaries. In the future,the PDQ Childhood Cerebellar Astrocytoma,PDQ Childhood Cerebral Astrocytoma,and PDQ Childhood Visual Pathway/Hypothalamic Glioma summaries.will be removed from the National Cancer ...
Childhood Brain and Spinal Cord Tumors Treatment Overview (PDQ®): Treatment - Patient Information [NCI] - nci_ncicdr0000257997-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Childhood Brain and Spinal Cord Tumors Treatment Overview
Neuroblastoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment of Stage 4S Neuroblastoma
Most cases of stage 4S neuroblastoma do not require therapy. However, if bulk disease is causing organ compromise and risk of death, low-dose to moderate-dose chemotherapy and/or radiation therapy is used. Eight percent to 10% of these patients will have MYCN amplification and are treated with high-risk protocols. (Refer to the Treatment of High-Risk Neuroblastoma section of this summary for more information about the treatment of stage 4S high-risk neuroblastoma.)Table 9. Children's Oncology Group (COG) Neuroblastoma Stage 4S Group Assignment Schema Used for COG-P9641 and COG-A3961 StudiesaINSS StageAgeMYCNStatusINPC ClassificationDNA PloidybRisk GroupINPC = International Neuroblastoma Pathologic Classification; INSS = International Neuroblastoma Staging System.a The COG-P9641 and COG-A3961 trials established the current standard of care for neuroblastoma patients in terms of risk group assignment and treatment strategies.b DNA Ploidy: DNA Index (DI) > 1 is favorable, = 1 is
Pituitary Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Pituitary Tumors
Pituitary tumors represent from 10% to 25% of all intracranial neoplasms. Depending on the study cited, pituitary tumors can be classified into three groups according to their biological behavior:[1,2]Benign adenoma.Invasive adenoma.Carcinoma. Adenomas comprise the largest portion of pituitary neoplasms with an overall estimated prevalence of approximately 17%. Only a minority of adenomas are symptomatic. In addition, pituitary adenomas may be distinguished anatomically as intrapituitary, intrasellar, diffuse, and invasive. Invasive adenomas, which account for approximately 35% of all pituitary neoplasms, may invade the dura mater, cranial bone, or sphenoid sinus. Carcinomas account for 0.1% to 0.2% of all pituitary tumors.[6,7]Clinical PresentationThe most characteristic-presenting features of pituitary adenomas include inappropriate pituitary hormone secretion and visual field deficits.Rare signs and symptoms of pituitary disease include:Cranial nerve palsies.Temporal
Childhood Ependymoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment of Newly Diagnosed Childhood Ependymoma
In the newly diagnosed patient, careful evaluation to fully determine the extent of disease must precede the treatment of ependymoma. Surgery should be performed in an attempt at maximal tumor reduction; children have improved progression-free survival (PFS) if there is minimal residual disease present after surgery.[1,2] Postoperatively, magnetic resonance imaging (MRI) should be performed to determine the extent of resection, although the rate of dissemination is low. If not performed preoperatively, MRI of the entire neuraxis should be obtained to evaluate for disease dissemination. Myxopapillary ependymomas, considered to be a benign histologic subtype of ependymoma, have a relatively high incidence of central nervous system (CNS) tumor dissemination at diagnosis and at follow-up, and require imaging of the complete cranial spinal axis at the time of diagnosis and during follow-up.[3,4] Patients with residual tumor or disseminated disease should be considered at high risk for
Pituitary Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (07 / 27 / 2012)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Stage Information for Pituitary TumorsUpdated staging information for 2010 (cited Edge et al. as reference 1).This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Childhood Ependymoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Histopathologic Classification of Childhood Ependymal Tumors
In the most recent World Health Organization (WHO) classification of brain tumors, ependymal tumors are classified into four main subtypes:Subependymoma (WHO Grade I).Myxopapillary ependymoma (WHO Grade I).Ependymoma (WHO Grade II). Variants include cellular, papillary, tanycytic, clear cell, and mixed.Anaplastic (also known as malignant) ependymoma (WHO Grade III).The subependymoma is a slow-growing benign neoplasm, typically attached to the ventricle wall, and is composed of glial tumor cell clusters embedded in a fibrillary matrix. The myxopapillary ependymoma arises almost exclusively in the location of the conus medullaris, cauda equina, and filum terminale of the spinal cord, and is characterized histologically by tumor cells arranged in a papillary manner around vascularized myxoid stromal cores.The ependymoma, which is considered a Grade II neoplasm originating from the walls of the ventricles or from the spinal canal, is composed of neoplastic ependymal cells.